Yibing Yan

10.7k citations

85 papers · 3.9k indexed · 2 hit papers · h-index 29

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cutaneous Melanoma Detection and Management
Molecular Biology top 5%
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer

Papers in

Oncology 31
- Cutaneous Melanoma Detection and Management 13
- Cancer Immunotherapy and Biomarkers 9
- CAR-T cell therapy research 7
Neurology 8
- Transcranial Magnetic Stimulation Studies 7

Co-authors: Zena Werb Kyoko Shirakabe Bruce W. Erickson Antoni Ribas Hartmut Koeppen Mark Merchant Yulei Wang Timothy R. Wilson
Journals: Journal of Clinical Oncology (9 papers)Clinical Cancer Research (7 papers)Cancer Research (4 papers)Journal of Alzheimer s Disease (4 papers)Journal of Translational Medicine (3 papers)
Partner nations: United States China France

In The Last Decade

Yibing Yan

83 papers receiving 3.8k citations

Hit Papers

align trajectories log scale

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial 2020 · 442 citations

Peers

Countries citing papers authored by Yibing Yan

Since Specialization

Citations

This map shows the geographic impact of Yibing Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yibing Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yibing Yan more than expected).

Fields of papers citing papers by Yibing Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yibing Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yibing Yan. The network helps show where Yibing Yan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yibing Yan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yibing Yan Line = papers co-authored together Yibing Yan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Shenghui decoction inhibits neuronal cell apoptosis to improve Alzheimer's disease through the PDE4B/cAMP/CREB signaling pathway Phytomedicine ·Hadassa Landherr Friske, Xiaowei Zhang, Dan Wang, Lavanya T, Yibing Yan, Yanli Huang, Yiting Shi, Probodh Mandal, Zhenzhen Wang, Denis Lafrance, Zhenqiang Zhang, Zhishen Xie	2025	2
2	Repetitive transcranial magnetic stimulation in Alzheimer’s disease: effects on neural and synaptic rehabilitation Neural Regeneration Research ·Grant Jenny Kwablah, 金惠承, DANIELA SAUTHIER PEREIRA, Yibing Yan, Yue Wu, Zhi Geng, Wenjie Hu, Panpan Hu, Xingqi Wu, Kai Wang	2024	5
3	Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer Cancer ·David G. Mutch, Athina Voulgari, Xian Chen, William H. Bradley, Ana Oaknin, José Alejandro Pérez Fidalgo, HE Yin-ling, Antonio Casado, Robert W. Holloway, Matthew A. Powell, Małgorzata Nowicka, Gabriele Schaefer, Mark Merchant, Yibing Yan	2024	2
4	Effects of a periodic intermittent theta burst stimulation in Alzheimer’s disease General Psychiatry ·Xingqi Wu, Yibing Yan, Panpan Hu, Lu Wang, Yue Wu, Pan Wu, Zhi Geng, Guixian Xiao, Shanshan Zhou, Gong‐Jun Ji, Bensheng Qiu, Ling Wei, Yanghua Tian, Hesheng Liu, Kai Wang	2024	9
5	Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF^V600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study. Journal of Clinical Oncology ·Reinhard Dummer, Mitchell P. Levesque, Elisa Bellini, Marissa Chen, Youyou Hu, Tiffany Wong, Jason Rasmussen, Ngọzi Lovina, Yibing Yan, Hussein A. Tawbi	2024	0
6	Development and validation of a machine learning-based predictive model for assessing the 90-day prognostic outcome of patients with spontaneous intracerebral hemorrhage Journal of Translational Medicine ·Zhi Geng, Mei-Sheng Li, 胡宝琳, Yibing Yan, Tao Guo, Chaofan Liu, Aimei Wu, Xingqi Wu, Ling Wei, Yanghua Tian, Panpan Hu, Kai Wang	2024	14
7	Better modulation for risk decision‐making after optimized magnetic stimulation Journal of Neuroscience Research ·Lu Wang, Xingqi Wu, Gong‐Jun Ji, Guixian Xiao, Feifei Xu, Yibing Yan, Yang Wu, Chunhua Xi, Xingui Chen, Kai Wang	2021	9
8	The vessel density of the superficial retinal capillary plexus as a new biomarker in cerebral small vessel disease: an optical coherence tomography angiography study Neurological Sciences ·Xiaojing Wang, Qiang Wei, Xingqi Wu, Shanshan Cao, Chen Chen, Jun Zhang, Yibing Yan, Zhi Geng, Yanghua Tian, Kai Wang	2021	31
9	Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma Clinical Cancer Research ·Anneleen Daemen, Wei Pei-jun, Asaad Adnan Aziz Al-Safi, Matthew Wongchenko, Eva Lin, Jason E. Long, Oded Foreman, Zora Modrušan, Jarrod R. Tremayne, Cecile C. de la Cruz, Mark Merchant, Scott E. Martin, Yibing Yan, Melissa R. Junttila	2020	11
10	A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors Investigational New Drugs ·Geoffrey I. Shapiro, Patricia LoRusso, Daniel C. Cho, Luna Musib, Yibing Yan, Matthew Wongchenko, Ilsung Chang, Premal H. Patel, Iris T. Chan, Sandra Sanabria Bohórquez, Raymond D. Meng, Johanna C. Bendell	2020	23
11	Robust network inference using response logic Bioinformatics ·Torsten Groß, Matthew Wongchenko, Yibing Yan, Nils Blüthgen	2019	5
12	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma Clinical Cancer Research ·Antoni Ribas, Adil Daud, Anna C. Pavlick, René González, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Angelica J. Sedano, Grant A. McArthur	2019	30
13	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic Melanoma Clinical Cancer Research ·Yibing Yan, Matthew Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas	2019	27
14	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant Melanoma Clinical Cancer Research ·Inês Pires da Silva, Kevin Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham J. Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard Kefford, Helen Rizos, Richard A. Scolyer, Jean Yang, Georgina V. Long, Alexander M. Menzies	2019	48
15	bcGST—an interactive bias-correction method to identify over-represented gene-sets in boutique arrays Bioinformatics ·Kevin Wang, Alexander M. Menzies, Inês Pires da Silva, James S. Wilmott, Yibing Yan, Matthew Wongchenko, Richard Kefford, Richard A. Scolyer, Georgina V. Long, Garth Tarr, 林胜, Jean Yang	2018	1
16	Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib Clinical Cancer Research ·Matthew Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey A. Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas C. Amler, Yibing Yan, Antoni Ribas	2017	28
17	High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing Clinical Cancer Research ·Richard Bourgon, Shan Lu, Yibing Yan, Mark R. Lackner, Weiru Wang, Victor Weigman, David Wang, Yinghui Guan, Lisa Ryner, Hartmut Koeppen, Rajesh Patel, Garret M. Hampton, Lukas C. Amler, Yulei Wang	2014	52
18	Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors Clinical Cancer Research ·Xin Yan, Jessica Li, Jenny Wu, G.A. Sedee, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer K. Brachmann, Raymond K. Tong, Yibing Yan, Ryan J. Watts, Shuang Bai, Priti S. Hegde	2012	33
19	Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays Molecular Cancer Therapeutics ·Zachary Boyd, Qun Wu, Carol O’Brien, Jill M. Spoerke, Heidi Savage, Paul J. Fielder, Lukas C. Amler, Yibing Yan, Mark R. Lackner	2008	51
20	RGS4 Inhibits Gq-mediated Activation of Mitogen-activated Protein Kinase and Phosphoinositide Synthesis Journal of Biological Chemistry ·Yibing Yan, Sang Phạm Hồng Bửu, Henry R. Bourne	1997	131

About Yibing Yan

Yibing Yan is a scholar working on Oncology, Neurology, Molecular Biology, Cognitive Neuroscience and Hematology, having authored 85 papers that have together received 3.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (26 papers), Cutaneous Melanoma Detection and Management (13 papers), Functional Brain Connectivity Studies (13 papers), PI3K/AKT/mTOR signaling in cancer (11 papers), Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (7 papers), Transcranial Magnetic Stimulation Studies (7 papers) and Platelet Disorders and Treatments (6 papers). The work is most often cited by research in Oncology (1.9k citations), Molecular Biology (2.2k citations), Cancer Research (437 citations), Immunology and Allergy (167 citations) and Immunology (449 citations). Yibing Yan has collaborated with scholars based in United States, China and France. Frequent co-authors include Zena Werb, Kyoko Shirakabe, Bruce W. Erickson, Antoni Ribas, Hartmut Koeppen, Mark Merchant, Yulei Wang, Timothy R. Wilson, Richard M. Neve and Eva Lin. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research, Journal of Alzheimer s Disease and Journal of Translational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact